Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Cardiopulmonary bypass (CPB) for cardiac operations may be accompanied by different patterns
of visceral underperfusion. This could result in clinical patterns of lactic acidosis but in
the most severe cases there is the risk for mesenteric infarction (0.2% of the cases). Renal
function as well may be impaired due to a low oxygen delivery, and acute renal failure occurs
in 1-2% of cases.
Fenoldopam mesilate is a selective splanchnic vasodilator when used at a dose < 0.1
mcg/kg/min.
The experimental hypothesis of this randomized, controlled trial (RCT) is that the use of
fenoldopam may determine a better visceral perfusion during CPB.